时间标签：数据日期 2026-11-01 · 生成时间 2026-11-01 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/31–2026/11/01 ｜ 情报发生日期 2026-11-01
证据级别：摘要级。本条依据 PubMed 结构化摘要与元数据撰写，付费墙全文未获取、未逐节核验，本站未做任何数值推算补全。
研究问题
To investigate the underlying therapeutic mechanisms of Jiangtang Xiaozhi formula (JTXZF, )) in the treatment of type 2 diabetes mellitus (T2DM).
方法
The effects of JTXZF on T2DM were evaluated using a db/db mouse model.
核心结论
Potential targets of JTXZF in ameliorating T2DM-related pancreatic beta-cell dedifferentiation were initially predicted using network pharmacology.；A beta-cell dedifferentiation model was established in Min6 cells viapalmitic acid (PA) intervention.；The impact of JTXZF on beta-cell dedifferentiation was assessed through Western blot (WB), immunofluorescence staining, real-time quantitative polymerase chain reaction (RT-qPCR), and siRNA transfection, focusing on the modulation of the phosphatidylinositol…
局限
（原文未给出可直接抽取的对应表述）
对本项目的价值
临床前机制证据，需评估物种外推与剂量可行性：代谢—器官轴是干预安全性的主要约束面。 ｜ 价值分 1.2/5（★☆☆☆☆）
全文来源
未取到全文 → 本卡为摘要级解读，未核验全文
原文题录
- 英文标题：Jiangtang Xiaozhi formula alleviates type 2 diabetes mellitus by improving islet beta-cell dedifferentiation: a network pharmacology-based study.
- 期刊与标识：Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · PMID 42958671 · DOI 10.19852/j.cnki.jtcm.2026.05.014
B 级证据分级：B 级（同行评议临床前研究，主要为动物模型）
本文核心结论来自动物模型或体外细胞学，属临床前证据，不能外推至人体。「延长健康寿命」「改善功能」等表述在小鼠中的意义，与人类临床结局之间仍有距离。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」（SOP §4.2 摘要级）撰写，依据期刊公开摘要与 PubMed 元数据；付费墙全文未获取之处已标注「待补全文」，未做任何数值推算补全。